Radiesse Calcium Hydroxylapatite Filler and Biostimulator
Overview
Radiesse (Merz Aesthetics) is an injectable dermal filler and collagen biostimulator based on calcium hydroxylapatite (CaHA) microspheres suspended in a carboxymethylcellulose (CMC) carrier gel. It was first approved by the FDA in 2006 for facial soft tissue augmentation and subsequently received FDA approval in 2015 specifically for the correction of volume deficit in the dorsal hands — an indication unique among injectable fillers. In Europe, Radiesse holds CE Class III certification.
What distinguishes Radiesse from hyaluronic acid fillers and from other biostimulators is its dual mechanism: it provides immediate volumetric correction through its CMC gel component while simultaneously stimulating the body's own collagen and elastin production through the CaHA microspheres. This combination makes Radiesse particularly useful in facial areas requiring structural support and volumisation as well as in skin quality applications where the biostimulatory effect is the primary goal.
The product cannot be reversed or dissolved — there is no antidote equivalent to hyaluronidase. This critical characteristic requires careful patient selection, thorough informed consent and injection by practitioners with a detailed knowledge of facial anatomy and vascular risk management.
Dual Mechanism of Action
The mechanism of action of Radiesse has two temporally distinct phases that together account for its durability and its dual-action profile.
In the immediate phase, the CMC carrier gel provides physical volume at the injection site. CMC is a biocompatible polymer derived from cellulose; it is well tolerated, maintains the CaHA microspheres in suspension and produces the immediate lifting and volumisation effect that patients and practitioners see at the time of treatment. This immediate volume is similar in principle to the volume provided by hyaluronic acid fillers, although CMC has different rheological properties and cannot be dissolved.
Over the following weeks and months, a biological phase begins. The CaHA microspheres — each 25 to 45 micrometres in diameter — are phagocytosed and processed by macrophages, creating a local inflammatory stimulus that activates fibroblasts. Activated fibroblasts produce new type I collagen and elastin fibres around and within the CaHA scaffold. As the CMC gel is gradually absorbed (over approximately 1 to 2 months), this neocollagenesis provides a natural structural scaffold that sustains and in some cases enhances the volumetric result.
Finally, the CaHA particles themselves are gradually broken down over 12 to 18 months into calcium ions and inorganic phosphate, which are the normal constituents of hydroxyapatite, the mineral component of bone and teeth. These ions are metabolised through normal physiological pathways, leaving no permanent synthetic material in the tissue. This full biodegradability is an important safety and patient reassurance attribute of Radiesse.
Composition and Microsphere Technology
Each 1.5 mL syringe of Radiesse contains CaHA microspheres at a concentration of approximately 30% by volume in a gel of sodium carboxymethylcellulose, glycerin and sterile water for injection. The microspheres are manufactured to a precise size range of 25 to 45 micrometres. This size range is important: particles smaller than 25 micrometres could theoretically be phagocytosed directly by macrophages, triggering a more pronounced inflammatory response. Particles larger than 45 micrometres resist phagocytosis and could potentially persist longer than desired or produce palpable deposits. The 25 to 45 micrometre range is chosen to optimise the balance between biostimulation, tolerability and biodegradation kinetics.
Radiesse is available in two syringe sizes (1.5 mL and 0.8 mL) and also in a formulation premixed with lidocaine (Radiesse+), which reduces injection discomfort without requiring separate topical anaesthesia in most cases. Practitioners can also add lidocaine directly to undiluted or diluted Radiesse before injection; the manufacturer provides guidance on safe mixing ratios.
FDA Approval and Regulatory Status
Radiesse received its first FDA PMA approval (K050423) in 2006 for the correction of moderate to severe facial wrinkles and folds, particularly nasolabial folds. This original approval was supported by controlled clinical trial data comparing Radiesse to human collagen (CosmoDerm), demonstrating superiority in wrinkle correction at 12 months. Additional facial indications including cheek augmentation were supported through subsequent clinical evidence and regulatory submissions.
In 2015, the FDA granted a specific approval for the use of Radiesse for the correction of moderate to severe volume deficit of the dorsal hands. This hand indication was supported by a randomised controlled trial demonstrating statistically significant improvement in hand appearance at 3 months post-injection compared to a sham control, with durability maintained through 12 months of follow-up. Radiesse remains the only FDA-approved injectable filler specifically indicated for hand augmentation.
In the European Union, Radiesse holds CE Class III certification under the applicable medical device directives and must comply with EU MDR post-market surveillance requirements. Merz Aesthetics maintains an active medical safety surveillance programme for the product globally.
Hyperdiluted Radiesse for Biostimulation
Hyperdiluted Radiesse has emerged over the past decade as a significant evolution in the use of CaHA technology. By diluting Radiesse 1:1 to 1:3 with sterile saline, lidocaine or a combination, the concentration of CaHA microspheres is reduced to the point where the product no longer provides meaningful immediate volume, but retains and in some formulations may enhance its biostimulatory properties.
The rationale for hyperdilution is to enable treatment of larger body surface areas — neck, décolleté, inner arms, thighs, abdomen, buttocks — where classical full-concentration Radiesse would be cost-prohibitive, difficult to distribute evenly and potentially result in visible or palpable deposits. At hyperdilution concentrations, the product spreads more evenly through the tissue via cannula-based injection and acts principally as a biostimulator, improving skin texture, elasticity and overall quality rather than providing structural volume.
Clinical studies on hyperdiluted Radiesse for body applications have shown statistically significant improvements in skin laxity scores, patient-reported outcomes and objective measures of skin elasticity, particularly in the neck and décolleté. Treatment protocols typically involve 2 to 3 sessions spaced 4 to 6 weeks apart, using 1.5 to 3 mL of diluted product per session depending on the area. Results are typically assessed at 3 to 6 months post-treatment. It is important to note that body biostimulation with hyperdiluted Radiesse remains an off-label indication in most regulatory jurisdictions, and practitioners should inform patients accordingly.
Hand Rejuvenation
The hands are one of the most visible indicators of biological age, yet they are frequently neglected in comprehensive facial rejuvenation strategies. Age-related changes in the hands include volume loss in the dorsal fat compartments, thinning of the skin, increased visibility of tendons, veins and extensor tendons, and solar-induced pigmentary changes. Radiesse was developed and clinically validated specifically for this indication.
The technique for hand treatment involves injecting undiluted or mildly diluted Radiesse into the subcutaneous tissue of the dorsal hand, typically using a cannula to minimise bruising and ensure even distribution. The CMC gel provides immediate volume improvement, obscuring the underlying structures, while the CaHA stimulates dermal and subcutaneous remodelling that improves skin texture and thickness over subsequent months. The result is a fuller, more youthful-appearing hand with less visible tendons and veins.
Clinical trial data supporting the FDA hand indication demonstrated that 92% of treated patients showed improvement in hand appearance at the primary endpoint, compared to 8% of sham-treated controls. Durability was maintained through 12 months of follow-up, with many patients maintaining improvement to 18 months. Common side effects include injection-site swelling, bruising and tenderness, all of which typically resolve within 1 to 2 weeks. The risk of nodule formation in the hands is low with proper cannula technique and placement in the correct tissue plane.
No Antidote: Clinical Implications
One of the most important safety differences between Radiesse and hyaluronic acid fillers is the absence of a reversal agent. HA fillers can be rapidly dissolved with hyaluronidase, providing a critical safety net in the event of vascular occlusion — one of the most serious complications of injectable filler treatment. CaHA cannot be dissolved with any currently available antidote.
This has significant implications for both patient selection and injection technique. Practitioners using Radiesse must have thorough knowledge of facial vascular anatomy, including the locations of the angular artery, facial artery, supratrochlear and supraorbital arteries, and the dorsal nasal artery. Danger zones for vascular injury — such as the nasolabial fold area, the glabella and the nose — must be approached with particular caution. The risk of intravascular injection can be reduced by using cannulas rather than needles in high-risk areas, by aspirating before injection (though the reliability of aspiration for detecting intravascular placement is debated), and by injecting in small boluses with continuous movement.
If a vascular occlusion with Radiesse is suspected, immediate consultation with an experienced specialist is essential. Management may include hyaluronidase injection (which can reduce associated oedema and inflammatory reaction, even though it does not dissolve the CaHA), warm compresses, aspirin and nitroglycerine paste for vasodilation, and, in severe cases, hyperbaric oxygen therapy. Prevention through meticulous technique remains the primary strategy.
Duration and Treatment Costs
Classic undiluted Radiesse for facial applications typically provides results lasting 12 to 18 months, with some patients reporting maintained improvement up to 24 months. The CaHA-stimulated neocollagenesis continues even after the initial CMC gel has been absorbed, which contributes to this extended duration compared to many HA fillers. Hyperdiluted Radiesse for body biostimulation applications generally produces results lasting 9 to 12 months, reflecting the lower concentration of CaHA and the different tissue environment.
The cost of Radiesse treatment in Germany typically ranges from approximately €300 to €600 per syringe (1.5 mL), with facial treatment costs varying based on the number of syringes required (typically 1 to 3 for full facial correction), the treating clinic and the practitioner's experience. Hand treatment using 1 to 2 syringes per hand may cost €400 to €1,000 per session. Hyperdiluted body treatments using multiple syringes may cost €600 to €1,500 per session depending on the area and treatment protocol. As with all aesthetic treatments, Radiesse is not covered by statutory health insurance in Germany.
Sources and Further Reading
- U.S. Food and Drug Administration. Summary of Safety and Effectiveness Data: Radiesse Injectable Implant, PMA K050423. FDA, 2006.
- U.S. Food and Drug Administration. 510(k) Premarket Notification: Radiesse for Hands, K143290. FDA, 2015.
- Merz Aesthetics. Radiesse: Instructions for Use and Clinical Summary. Current edition.
- Alam M, Havey J, Pace N, et al. Large-particle calcium hydroxylapatite injection for correction of facial wrinkles and depressions. J Am Acad Dermatol. 2011;65(1):92–96.
- Moers-Carpi MM, Tufet JO. Calcium hydroxylapatite versus nonanimal stabilised hyaluronic acid for the correction of nasolabial folds: a 12-month, multicentre, prospective, randomised, controlled trial. Dermatol Surg. 2008;34(2):210–215.
- Goldie K, Peeters W, Alghoul M, et al. Global Consensus Guidelines for the Injection of Diluted and Hyperdiluted Calcium Hydroxylapatite for Skin Tightening. Dermatol Surg. 2018;44(Suppl 1):S32–S41.